297 related articles for article (PubMed ID: 32341577)
1. Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome.
Dziekan JM; Wirjanata G; Dai L; Go KD; Yu H; Lim YT; Chen L; Wang LC; Puspita B; Prabhu N; Sobota RM; Nordlund P; Bozdech Z
Nat Protoc; 2020 Jun; 15(6):1881-1921. PubMed ID: 32341577
[TBL] [Abstract][Full Text] [Related]
2. A proteomic glimpse into the effect of antimalarial drugs on Plasmodium falciparum proteome towards highlighting possible therapeutic targets.
Dousti M; Manzano-Román R; Rashidi S; Barzegar G; Ahmadpour NB; Mohammadi A; Hatam G
Pathog Dis; 2021 Jan; 79(1):. PubMed ID: 33202000
[TBL] [Abstract][Full Text] [Related]
3. Multi-omic Characterization of the Mode of Action of a Potent New Antimalarial Compound, JPC-3210, Against
Birrell GW; Challis MP; De Paoli A; Anderson D; Devine SM; Heffernan GD; Jacobus DP; Edstein MD; Siddiqui G; Creek DJ
Mol Cell Proteomics; 2020 Feb; 19(2):308-325. PubMed ID: 31836637
[TBL] [Abstract][Full Text] [Related]
4. A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry.
Penarete-Vargas DM; Boisson A; Urbach S; Chantelauze H; Peyrottes S; Fraisse L; Vial HJ
PLoS One; 2014; 9(12):e113918. PubMed ID: 25470252
[TBL] [Abstract][Full Text] [Related]
5. Identification of Antimalarial Compounds That Require CLAG3 for Their Uptake by
Mira-Martínez S; Pickford AK; Rovira-Graells N; Guetens P; Tintó-Font E; Cortés A; Rosanas-Urgell A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782998
[TBL] [Abstract][Full Text] [Related]
6. The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials.
Sheridan CM; Garcia VE; Ahyong V; DeRisi JL
Malar J; 2018 Dec; 17(1):465. PubMed ID: 30541569
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
8. Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit
Sosa Y; Deniskin R; Frame IJ; Steiginga MS; Bandyopadhyay D; Graybill TL; Kallal LA; Ouellette MT; Pope AJ; Widdowson KL; Young RJ; Akabas MH
ACS Infect Dis; 2019 Oct; 5(10):1738-1753. PubMed ID: 31373203
[TBL] [Abstract][Full Text] [Related]
9. The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens.
Hapuarachchi SV; Cobbold SA; Shafik SH; Dennis AS; McConville MJ; Martin RE; Kirk K; Lehane AM
PLoS Pathog; 2017 Feb; 13(2):e1006180. PubMed ID: 28178359
[TBL] [Abstract][Full Text] [Related]
10. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
Ellekvist P; Colding H
Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of Plasmodium falciparum schizonts reveals heparin-binding merozoite proteins.
Zhang Y; Jiang N; Lu H; Hou N; Piao X; Cai P; Yin J; Wahlgren M; Chen Q
J Proteome Res; 2013 May; 12(5):2185-93. PubMed ID: 23566259
[TBL] [Abstract][Full Text] [Related]
12. Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections.
Cowell AN; Winzeler EA
Genome Med; 2019 Oct; 11(1):63. PubMed ID: 31640748
[TBL] [Abstract][Full Text] [Related]
13. A Novel Methodology for Bioenergetic Analysis of Plasmodium falciparum Reveals a Glucose-Regulated Metabolic Shift and Enables Mode of Action Analyses of Mitochondrial Inhibitors.
Sakata-Kato T; Wirth DF
ACS Infect Dis; 2016 Dec; 2(12):903-916. PubMed ID: 27718558
[TBL] [Abstract][Full Text] [Related]
14. In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum.
Phaiphinit S; Pattaradilokrat S; Lursinsap C; Plaimas K
Infect Genet Evol; 2016 Jan; 37():237-44. PubMed ID: 26626103
[TBL] [Abstract][Full Text] [Related]
15. A high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytes.
Winterberg M; Kirk K
Sci Rep; 2016 Jul; 6():29241. PubMed ID: 27385291
[TBL] [Abstract][Full Text] [Related]
16. The treatment of Plasmodium falciparum-infected erythrocytes with chloroquine leads to accumulation of ferriprotoporphyrin IX bound to particular parasite proteins and to the inhibition of the parasite's 6-phosphogluconate dehydrogenase.
Famin O; Ginsburg H
Parasite; 2003 Mar; 10(1):39-50. PubMed ID: 12669348
[TBL] [Abstract][Full Text] [Related]
17. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
Herman JD; Pepper LR; Cortese JF; Estiu G; Galinsky K; Zuzarte-Luis V; Derbyshire ER; Ribacke U; Lukens AK; Santos SA; Patel V; Clish CB; Sullivan WJ; Zhou H; Bopp SE; Schimmel P; Lindquist S; Clardy J; Mota MM; Keller TL; Whitman M; Wiest O; Wirth DF; Mazitschek R
Sci Transl Med; 2015 May; 7(288):288ra77. PubMed ID: 25995223
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways.
Allman EL; Painter HJ; Samra J; Carrasquilla M; Llinás M
Antimicrob Agents Chemother; 2016 Nov; 60(11):6635-6649. PubMed ID: 27572391
[TBL] [Abstract][Full Text] [Related]
19. Determining the Mode of Action of Antimalarial Drugs Using Time-Resolved LC-MS-Based Metabolite Profiling.
Cobbold SA; McConville MJ
Methods Mol Biol; 2019; 1859():225-239. PubMed ID: 30421232
[TBL] [Abstract][Full Text] [Related]
20. Evidence of G-Protein-Coupled Receptors (GPCR) in the Parasitic Protozoa
Pereira PHS; Garcia CRS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
